bioTheranosticsMayo Clinic and Mayo Medical Laboratories will offer the CancerTYPE ID® molecular cancer classification test from bioTheranostics, San Diego, as part of its surgical pathology consultants, to aid in the management of patients with metastatic cancer.

The test will be available to Mayo Clinic physicians and patients, and to more than 5,000 hospitals worldwide served by Mayo Medical Laboratories.

The test, a molecular cancer classifier, predicts tumor type in patients with metastatic cancers, which affect more than 400,000 patients in the United States each year and are among the most difficult to diagnose and treat. It is supported by clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification, and impact on patient outcomes, according to the company.

[Source: bioTheranostics]